Compare e l f Beauty Inc (ELF) vs 10X Genomics Inc (TXG) Price & Performance

ELF Beauty trades at $94.33, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2027 results, beating EPS estimates with $1.75 versus $0.71 expected, driven by 36% sales growth from the Rhode brand and international expansion. Valuation metrics show a high P/E of 96.93, reflecting premium pricing for growth. Recent news highlights a $50 million tariff refund boosting profits and expansion into hair care products.

Outlook remains positive due to consistent revenue growth and raised guidance, but risks include high valuation dependence on acquisitions and organic unit declines. Analyst consensus is mixed with a $91.14 price target, suggesting cautious optimism amid execution risks.

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.